Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Pacific Edge Limited ( (PFGTF) ) just unveiled an update.
Pacific Edge Limited announced the lapse of 322,233 options to acquire ordinary shares, representing 0.03% of the total ordinary shares on issue. This lapse occurred because the conditional rights to these securities expired, leaving the company with 1,022,135,460 ordinary shares and 47,517,663 options to acquire ordinary shares. The announcement reflects a minor adjustment in the company’s capital structure, with limited immediate impact on its operations or market positioning.
More about Pacific Edge Limited
Pacific Edge Limited operates in the biotechnology industry, focusing on the development and commercialization of diagnostic tests for the early detection and management of cancer. The company primarily offers non-invasive tests for bladder cancer, aiming to improve patient outcomes and reduce healthcare costs.
Find detailed analytics on PFGTF stock on TipRanks’ Stock Analysis page.